Zivo Bioscience (ZIVO)

$10.25 0.00 (N/A)
Market Cap 40.77M
Revenue (ttm) 160,000.00
Net Income (ttm) -13.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -8,362.50%
Debt to Equity Ratio 0.00
Volume 400
Avg Vol 1,326
Day's Range N/A - N/A
Shares Out 3.98M
Stochastic %K 53%
Beta 0.19
Analysts Hold
Price Target $12.00

Company Profile

ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 248 452 9866
Address:
2125 Butterfield Drive, Suite 100, Troy, United States
nick275
nick275 Apr. 25 at 4:10 PM
$ZIVO Strome a buyer, not a seller, which makes me even more bullish. Glad I was able to pick up shares last week and will be buying more on Monday. Who is selling? Maybe Cornell?
0 · Reply
trprofit
trprofit Apr. 25 at 12:41 PM
$ZIVO Looks he's getting ready!
0 · Reply
AmigoMike
AmigoMike Apr. 24 at 10:25 PM
$ZIVO LOL. SEC filing today. Strome bought 100k at $2 earlier this week. https://ir.zivobioscience.com/sec-filings-email/content/0001213900-26-047650/ownership.html So much for the presumption of Strome being a seller.
0 · Reply
AmigoMike
AmigoMike Apr. 23 at 4:05 PM
$ZIVO @trprofit You'll also notice that ZIVO's new production partner CYAN did the same thing earlier this year. Announced dropping SEC reporting. But appears like they are continuing "disclosures" under the OTCID tier and not going to pink sheets. These filed all the necessary disclosures to keep the OTC listing last week. My guess is the topic had to come up when talking with CYAN about manufacturing deal ........ could even be where ZIVO got the idea. I am hoping ZIVO follows the same path at least to maintain OTC listing
0 · Reply
AmigoMike
AmigoMike Apr. 23 at 4:00 PM
$ZIVO @trprofit I actually won't be surprised if the stock ... does not ... take off ... even with the right news. Payne is horrific when it comes to PRs. They leave more questions than answers. Payne could easily post an updated statement on the plan for the reporting and listing ... yet he doesn't do it .... and meanwhile the stock goes into the toilet again. That is partly due to FAILURE IN COMMUNICATION that is easily rectified. Otherwise its all FUD. The plan is likely getting to CF+ via algae sales as soon as possible with a slimmed down corporate overhead. Insiders will continue to fund the needs to get there. If cash flow warrants it, paying dividends is certainly a possibility. And until I actually see it in writing, its uncertain where the listing will end up.
0 · Reply
trprofit
trprofit Apr. 22 at 8:17 PM
$ZIVO These guys like to put out news after the bell on Fridays. With the right news, this should really take off, non-reporting "Pinky" or not.
2 · Reply
nick275
nick275 Apr. 21 at 10:21 PM
$ZIVO My guess is given the volume remaining the institutional holder needs to sell, this could get into the pennies. I assume the only buyers are those already familiar with the stock, which is a handful of people and they can let it continue to fall. The insiders who have been the buyers previously presumably supported delisting since they no longer want to continue buying to prop up the company. They hold a majority of the company shares and have no reason to buy more. Interesting to see if any new random retail buyers are accumulating. I doubt it since this likely will not be able to be traded easily in the near future and is a long, risky play.
0 · Reply
Wischmop
Wischmop Apr. 21 at 8:21 AM
$SGMO Your skepticism is justified; it's extremely rare, but possible. Novavax 2019: The share price was around $0.35. They missed all NASDAQ deadlines, performed a 1:20 reverse stock split, and were on the ropes. The stock skyrocketed from under $4 to over $300. However, these shares didn't go OTC yet; it's just about exploring the possibilities if the technology is right. A breakthrough (like Sangamo's Fabry approval or the Lilly deal) can rehabilitate a nearly dead stock. 2. Zivo Bioscience ($ZIVO) – The classic OTC route They used their time on the OTC market, then performed a reverse stock split and met the requirements for relisting. • Lesson for SGMO: The OTC market isn't a dead end, but rather a "penalty area." If you deliver there, NASDAQ will let you back in. I believe SGMO could be that exception. There are important dates coming up in June, a possible shareholders' meeting, see if she's speaking at an important conference, let's see if there's a connection.
2 · Reply
nick275
nick275 Apr. 20 at 2:27 PM
$ZIVO if Strome is the seller, this could take awhile. I estimate almost 200,000 more shares to liquidate.
0 · Reply
nick275
nick275 Apr. 18 at 1:31 PM
$ZIVO my guess is Strome is liquidating and moving on. Almost 200k shares traded the last few weeks and trading pattern indicates this is mostly from one holder. He is the largest institutional holder. I had no issues getting shares at the bid this week. It is going to be a long road ahead for those of us left, but this still seems like the right move to conserve cash and now it is up to the board to generate revenue.
1 · Reply
Latest News on ZIVO
No data available.
nick275
nick275 Apr. 25 at 4:10 PM
$ZIVO Strome a buyer, not a seller, which makes me even more bullish. Glad I was able to pick up shares last week and will be buying more on Monday. Who is selling? Maybe Cornell?
0 · Reply
trprofit
trprofit Apr. 25 at 12:41 PM
$ZIVO Looks he's getting ready!
0 · Reply
AmigoMike
AmigoMike Apr. 24 at 10:25 PM
$ZIVO LOL. SEC filing today. Strome bought 100k at $2 earlier this week. https://ir.zivobioscience.com/sec-filings-email/content/0001213900-26-047650/ownership.html So much for the presumption of Strome being a seller.
0 · Reply
AmigoMike
AmigoMike Apr. 23 at 4:05 PM
$ZIVO @trprofit You'll also notice that ZIVO's new production partner CYAN did the same thing earlier this year. Announced dropping SEC reporting. But appears like they are continuing "disclosures" under the OTCID tier and not going to pink sheets. These filed all the necessary disclosures to keep the OTC listing last week. My guess is the topic had to come up when talking with CYAN about manufacturing deal ........ could even be where ZIVO got the idea. I am hoping ZIVO follows the same path at least to maintain OTC listing
0 · Reply
AmigoMike
AmigoMike Apr. 23 at 4:00 PM
$ZIVO @trprofit I actually won't be surprised if the stock ... does not ... take off ... even with the right news. Payne is horrific when it comes to PRs. They leave more questions than answers. Payne could easily post an updated statement on the plan for the reporting and listing ... yet he doesn't do it .... and meanwhile the stock goes into the toilet again. That is partly due to FAILURE IN COMMUNICATION that is easily rectified. Otherwise its all FUD. The plan is likely getting to CF+ via algae sales as soon as possible with a slimmed down corporate overhead. Insiders will continue to fund the needs to get there. If cash flow warrants it, paying dividends is certainly a possibility. And until I actually see it in writing, its uncertain where the listing will end up.
0 · Reply
trprofit
trprofit Apr. 22 at 8:17 PM
$ZIVO These guys like to put out news after the bell on Fridays. With the right news, this should really take off, non-reporting "Pinky" or not.
2 · Reply
nick275
nick275 Apr. 21 at 10:21 PM
$ZIVO My guess is given the volume remaining the institutional holder needs to sell, this could get into the pennies. I assume the only buyers are those already familiar with the stock, which is a handful of people and they can let it continue to fall. The insiders who have been the buyers previously presumably supported delisting since they no longer want to continue buying to prop up the company. They hold a majority of the company shares and have no reason to buy more. Interesting to see if any new random retail buyers are accumulating. I doubt it since this likely will not be able to be traded easily in the near future and is a long, risky play.
0 · Reply
Wischmop
Wischmop Apr. 21 at 8:21 AM
$SGMO Your skepticism is justified; it's extremely rare, but possible. Novavax 2019: The share price was around $0.35. They missed all NASDAQ deadlines, performed a 1:20 reverse stock split, and were on the ropes. The stock skyrocketed from under $4 to over $300. However, these shares didn't go OTC yet; it's just about exploring the possibilities if the technology is right. A breakthrough (like Sangamo's Fabry approval or the Lilly deal) can rehabilitate a nearly dead stock. 2. Zivo Bioscience ($ZIVO) – The classic OTC route They used their time on the OTC market, then performed a reverse stock split and met the requirements for relisting. • Lesson for SGMO: The OTC market isn't a dead end, but rather a "penalty area." If you deliver there, NASDAQ will let you back in. I believe SGMO could be that exception. There are important dates coming up in June, a possible shareholders' meeting, see if she's speaking at an important conference, let's see if there's a connection.
2 · Reply
nick275
nick275 Apr. 20 at 2:27 PM
$ZIVO if Strome is the seller, this could take awhile. I estimate almost 200,000 more shares to liquidate.
0 · Reply
nick275
nick275 Apr. 18 at 1:31 PM
$ZIVO my guess is Strome is liquidating and moving on. Almost 200k shares traded the last few weeks and trading pattern indicates this is mostly from one holder. He is the largest institutional holder. I had no issues getting shares at the bid this week. It is going to be a long road ahead for those of us left, but this still seems like the right move to conserve cash and now it is up to the board to generate revenue.
1 · Reply
trprofit
trprofit Apr. 11 at 7:49 PM
$ZIVO WTF, eh?
2 · Reply
nick275
nick275 Apr. 11 at 6:41 PM
$ZIVO June 20, 2025 — ZIVO enters a relationship with a leading global animal-health company ZIVO announced a relationship with one of the world’s leading animal-health companies to advance immune-enhancing poultry compounds across multiple market segments.
0 · Reply
nick275
nick275 Apr. 11 at 6:41 PM
$ZIVO February 6, 2025 — ZIVO launches a second University of Delaware avian-influenza study ZIVO said the follow-up study would optimize formulations and treatment protocols.
0 · Reply
nick275
nick275 Apr. 11 at 3:37 AM
$ZIVO December 20, 2024 — University of Delaware avian-influenza study shows reduced shedding and delayed transmission
0 · Reply
nick275
nick275 Apr. 11 at 3:36 AM
$ZIVO August 23, 2024 — ZIVO reports favorable results from that confirmatory study ZIVO said the study showed statistically significant improvements in feed-conversion ratio and intestinal lesion scores when its product was used alongside either an ionophore or vaccine.
0 · Reply
nick275
nick275 Apr. 11 at 3:36 AM
$ZIVO September 19, 2023 — ZIVO reports statistically significant coccidiosis efficacy under simulated commercial conditions ZIVO said treated birds showed statistically significant improvements across broiler-health measures under a challenge model meant to resemble commercial outbreaks.
0 · Reply
nick275
nick275 Apr. 11 at 3:35 AM
$ZIVO March 18, 2020 — ZIVO reports longer-term broiler growth and nutrition benefits ZIVO said early-life administration of its ingredient led to benefits observed over the full 42-day broiler cycle
0 · Reply
nick275
nick275 Apr. 11 at 3:34 AM
$ZIVO September 19, 2017 — ZIVO and NutriQuest report encouraging poultry-study results ZIVO said poultry studies supported continued work toward market entry and parallel regulatory progress.
0 · Reply
nick275
nick275 Apr. 11 at 3:34 AM
$ZIVO September 11, 2017 — ZIVO begins the final phase of a bovine mastitis efficacy study ZIVO announced the final phase of its mastitis validation program and said mechanistic work such as gene-expression analysis could be included.
0 · Reply
nick275
nick275 Apr. 11 at 3:34 AM
$ZIVO July 11, 2017 — ZIVO contracts with Algatek in Spain to expand production and regulatory readiness ZIVO entered a pilot program with Algatek Asturias to test production of its strain in commercial photobioreactors under food-pharma grade conditions.
0 · Reply
nick275
nick275 Apr. 11 at 3:33 AM
$ZIVO December 15, 2016 — ZIVO and NutriQuest agree to pursue poultry and swine feed applications ZIVO announced an agreement with NutriQuest to jointly pursue feed and feed-additive opportunities in poultry and swine.
0 · Reply
nick275
nick275 Apr. 11 at 3:33 AM
$ZIVO March 3, 2016 — ZIVO activates pilot production and validation work for bovine feed-additive programs ZIVO said new funding allowed it to move forward with pilot production, post-processing, encapsulation, pelletizing, and additional validation around bovine feed and mastitis-related applications.
0 · Reply